Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
Science Advances · 2023
DOI: 10.1126/sciadv.adh0831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Ebru Boslem und 22 weiteren Autor:innen. Beteiligte Einrichtung: Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
The incidence of hepatocellular carcinoma (HCC) is rapidly rising largely because of increased obesity leading to nonalcoholic steatohepatitis (NASH), a known HCC risk factor. There are no approved treatments to treat NASH. Here, we first used single-nucleus RNA sequencing to characterize a mouse model that mimics human NASH–driven HCC, the MUP-uPA mouse fed a high-fat diet. Activation of endoplasmic reticulum (ER) stress and inflammation was observed in a subset of hepatocytes that was enriched in mice that progress to HCC. We next treated MUP-uPA mice with the ER stress inhibitor BGP-15 and soluble gp130Fc, a drug that blocks inflammation by preventing interleukin-6 trans-signaling. Both drugs have progressed to phase 2/3 human clinical trials for other indications. We show that this combined therapy reversed NASH and reduced NASH-driven HCC. Our data suggest that these drugs could provide a potential therapy for NASH progression to HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
- Garvan Institute of Medical Research, Sydney, Australia.
- Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia.
- Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA 6102, Australia.
- Wellcome Sanger Institute, Cambridge, UK.
- EMBL's European Bioinformatics Institute, Cambridge UK.
ORCID-Profile: Ebru Boslem, Saskia Reibe, Rodrigo Carlessi, Benoit Smeuninx, Surafel Tegegne, Max Nobis, Cameron Nowell, Neil Horadagoda, Paul Timpson, Alistair R R Forrest, Janina E E Tirnitz-Parker, Peter J Meikle, Stefan Rose-John, Mark A Febbraio
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- NIEHS NIH HHS
- NCI NIH HHS
Zitieren
APA
Boslem, E., Reibe, S., Carlessi, R., Smeuninx, B., Tegegne, S., Egan, C. L., McLennan, E., Terry, L. V., Nobis, M., Mu, A., Nowell, C., Horadagoda, N., Henstridge, D. C., Mellett, N. A., Timpson, P., Jones, M., Denisenko, E., Forrest, A. R. R., Tirnitz-Parker, J. E. E., …, & Febbraio, M. A. (2023). Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC. Science Advances. https://doi.org/10.1126/sciadv.adh0831
Vancouver
Boslem E, Reibe S, Carlessi R, Smeuninx B, Tegegne S, Egan CL, et al. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC. Science Advances. 2023. doi:10.1126/sciadv.adh0831
BibTeX
@article{Boslem2023,
author = {Boslem, Ebru and Reibe, Saskia and Carlessi, Rodrigo and Smeuninx, Benoit and Tegegne, Surafel and Egan, Casey L and McLennan, Emma and Terry, Lauren V and Nobis, Max and Mu, Andre and Nowell, Cameron and Horadagoda, Neil and Henstridge, Darren C and Mellett, Natalie A and Timpson, Paul and Jones, Matthew and Denisenko, Elena and Forrest, Alistair R R and Tirnitz-Parker, Janina E E and Meikle, Peter J and Rose-John, Stefan and Karin, Michael and Febbraio, Mark A},
title = {Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC},
journal = {Science Advances},
year = {2023},
doi = {10.1126/sciadv.adh0831}
}
EUVIMED